The pharmaceuticalindustry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Bridged diaryl derivatives-based cancer drug compositions.

According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 areas of innovation that will shape the future of the industry.

Bridged diaryl derivatives-based cancer drug compositions is a key innovation area in immuno-oncology

Diaryl-ether is a scaffold found in natural products, synthetic organic compounds,  and innovative molecules. Owing to its unique physicochemical properties and potential biological activities, it is widely used in  anti-cancer, anti-diabetic, and anti-tubercular agents. Diaryl-ethers can be synthesised in three ways, including Ullmann ether synthesis, Buchwald Pd-catalysed ether synthesis and via aromatic nucleophilic substitution (SNAr)-based addition reactions. Based on the ease of synthesis and its  biological activity, the bridged diaryl skeleton structure is widely used for anti-cancer drugs.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.  According to GlobalData, there are 50+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of bridged diaryl derivatives-based cancer drug compositions.

Key players in bridged diaryl derivatives-based cancer drug compositions – a disruptive innovation in the pharmaceutical industry  

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators. 

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’. 

Patent volumes related to bridged diaryl derivatives-based cancer drug compositions

Company Total patents (2010 - 2021) Premium intelligence on the world's largest companies
Bristol-Myers Squibb 205 Unlock company profile
Pfizer 169 Unlock company profile
ImmunoGen 151 Unlock company profile
Bayer 105 Unlock company profile
E. Merck 101 Unlock company profile
Gilead Sciences 94 Unlock company profile
Regeneron Pharmaceuticals 92 Unlock company profile
Enanta Pharmaceuticals 83 Unlock company profile
GSK 73 Unlock company profile
Abbott Laboratories 69 Unlock company profile
Revolution Medicines 65 Unlock company profile
F. Hoffmann-La Roche 63 Unlock company profile
Eurofins Scientific 57 Unlock company profile
Philip Morris International 45 Unlock company profile
Oncodesign 43 Unlock company profile
Catalent 41 Unlock company profile
CTI BioPharma 38 Unlock company profile
HitGen 35 Unlock company profile
AbbVie 35 Unlock company profile
Merck & Co 30 Unlock company profile
Cypralis 29 Unlock company profile
Les Laboratoires Servier 24 Unlock company profile
Blue Sail Medical 23 Unlock company profile
Flarer 23 Unlock company profile
Novartis 20 Unlock company profile
S*BIO 20 Unlock company profile
Aprea Therapeutics 19 Unlock company profile
Aeterna Zentaris 17 Unlock company profile
Nestle 17 Unlock company profile
Hangzhou DAC Biotech 16 Unlock company profile
Molecular Targeting Technologies 15 Unlock company profile
Scohia Pharma 12 Unlock company profile
InnoCare Pharma 12 Unlock company profile
Biotronik 12 Unlock company profile
Youngjin Pharmaceutical 11 Unlock company profile
Helmholtz Association of German Research Centres 11 Unlock company profile
Suzhou Teligene 10 Unlock company profile
Hangzhou Zylox Pharma 10 Unlock company profile
Suzhou M-Conj Biotech 9 Unlock company profile
CytRx 9 Unlock company profile
Pharma Mar 9 Unlock company profile
Curia 9 Unlock company profile
Bio-Thera Solutions 9 Unlock company profile
Teva Pharmaceutical Industries 8 Unlock company profile
Amgen 8 Unlock company profile
Astro Bidco 8 Unlock company profile
Fresenius 8 Unlock company profile
SymBio Pharmaceuticals 7 Unlock company profile
Sanofi 7 Unlock company profile
AbTis 5 Unlock company profile

Source: GlobalData Patent Analytics

Turning Point Therapeutics (now part of Bristol-Myers Squibb) is a leader in developing diaryl derivatives-based anti-cancer drugs. The company has filed several patents and is developing drugs such as repotrectinib for the treatment of solid tumours. Repotrectinib is in Phase II clinical trials for multiple oncology indications. The company has also partnered with ZaiLab for its development in China.

In terms of application diversity, AbTis is the top company followed by Bayer and Astro Bidco. By  geographic reach, Enanta Pharmaceuticals holds the top position. Gilead Sciences and Eurofins Scientific are in the second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Immuno-Oncology – Thematic Research.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.